Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol

Lanell M. Peterson, David A. Mankoff, Thomas Lawton, Kevin Yagle, Erin K. Schubert, Svetlana Stekhova, Allen Gown, Jeanne M. Link, Timothy Tewson, Kenneth A. Krohn

Research output: Contribution to journalArticle

153 Scopus citations

Abstract

The PET compound 18F-fluoroestradiol (18F-FES) has been developed and tested as an agent for the imaging of estrogen receptor (ER) expression in vivo. 18F-FES uptake has been shown to correlate with ER expression assayed in vitro by radioligand binding; however, immunohistochemistry (IHC) rather than radioligand binding is used most often to measure ER expression in clinical practice. We therefore compared 18F-FES uptake with ER expression assayed in vitro by IHC with both qualitative and semiquantitative measures. Methods: Seventeen patients with primary or metastatic breast cancer were studied with dynamic 18F-FES PET; cancer tissue samples, collected close to the time of imaging, were assayed for ER expression by IHC. For each tumor, partial-volume-corrected measures of 18F-FES uptake were compared with ER expression measured by 3 different ER scoring methods: qualitative scoring (0-31), the Allred score (0-10), and a computerized IHC index. Results: There was excellent agreement (r=0.99) between observers using IHC as well as the different methods of measuring ER content (P < 0.001). ER-negative tumors had 18F-FES partial-volume-corrected standardized uptake values of less than 1.0, whereas ER-positive tumors had values above 1.1. Correlation coefficients for the different measures of ER content and the different measures of 18F-FES uptake ranged from 0.57 to 0.73, with the best correlation being between the computerized IHC index and 18F-FES partial-volume-corrected standardized uptake values. Conclusion: Our results showed good agreement between 18F-FES PET and ER expression measured by IHC. 18F-FES imaging may be a useful tool for aiding in the assessment of ER status, especially in patients with multiple tumors or for tumors that are difficult to biopsy.

Original languageEnglish (US)
Pages (from-to)367-374
Number of pages8
JournalJournal of Nuclear Medicine
Volume49
Issue number3
DOIs
StatePublished - Mar 1 2008

Keywords

  • Breast cancer
  • Estrogen receptor
  • F-FES PET
  • IHC
  • Tracer uptake

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Quantitative imaging of estrogen receptor expression in breast cancer with PET and <sup>18</sup>F-fluoroestradiol'. Together they form a unique fingerprint.

  • Cite this

    Peterson, L. M., Mankoff, D. A., Lawton, T., Yagle, K., Schubert, E. K., Stekhova, S., Gown, A., Link, J. M., Tewson, T., & Krohn, K. A. (2008). Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. Journal of Nuclear Medicine, 49(3), 367-374. https://doi.org/10.2967/jnumed.107.047506